Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Marth

Showing results (151-160 of 237) with videos related to

Pageof 24
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 5, 2024
Tumoral programmed cell death 1 (PD1) expression in endometrial carcinoma is a prognostic marker for patient outcomeBarin Feroz, Teresa L Pan, Katharina Leitner, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2016
Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patientsIgnace Vergote, Susana Banerjee, Anne-Marie Gerdes, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 23, 2013
Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancerTanja Fehm, Malgorzata Banys, Brigitte Rack, et al.
Acta Obstetricia Et Gynecologica Scandinavica|December 22, 2025
Biopsy-proven residual cervical cancer at the end of combined chemoradiation predicts poor outcome-Retrospective single-center cohort studyChristoph Ebner, Ricarda Purtscheller, Barin Feroz, et al.
Gynecologic Oncology|March 4, 2008
Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survivalDavid S Alberts, Christian Marth, Ronald D Alvarez, et al.
BMC Cancer|October 17, 2012
Adherence evaluation of endocrine treatment in breast cancer: methodological aspectsAnne S Oberguggenberger, Monika Sztankay, Beate Beer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 17, 2012
The N-terminally truncated p53 isoform Δ40p53 influences prognosis in mucinous ovarian cancerGerda Hofstetter, Astrid Berger, Regina Berger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursorsAndreas Widschwendter, Conny Gattringer, Lennart Ivarsson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 7, 2026
The impact of BRCA status on the efficacy of paclitaxel monotherapy in recurrent ovarian cancerGiorgia Russo, Adriana Ionelia Apostol, Ilary Ruscito, et al.
BMC Cancer|February 17, 2016
Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancerGabriel Schmid, Sara Notaro, Daniel Reimer, et al.
Pageof 24

Showing results (151-160 of 237) with videos related to

Sort By:
Pageof 24
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 5, 2024
Tumoral programmed cell death 1 (PD1) expression in endometrial carcinoma is a prognostic marker for patient outcomeBarin Feroz, Teresa L Pan, Katharina Leitner, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2016
Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patientsIgnace Vergote, Susana Banerjee, Anne-Marie Gerdes, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 23, 2013
Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancerTanja Fehm, Malgorzata Banys, Brigitte Rack, et al.
Acta Obstetricia Et Gynecologica Scandinavica|December 22, 2025
Biopsy-proven residual cervical cancer at the end of combined chemoradiation predicts poor outcome-Retrospective single-center cohort studyChristoph Ebner, Ricarda Purtscheller, Barin Feroz, et al.
Gynecologic Oncology|March 4, 2008
Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survivalDavid S Alberts, Christian Marth, Ronald D Alvarez, et al.
BMC Cancer|October 17, 2012
Adherence evaluation of endocrine treatment in breast cancer: methodological aspectsAnne S Oberguggenberger, Monika Sztankay, Beate Beer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 17, 2012
The N-terminally truncated p53 isoform Δ40p53 influences prognosis in mucinous ovarian cancerGerda Hofstetter, Astrid Berger, Regina Berger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursorsAndreas Widschwendter, Conny Gattringer, Lennart Ivarsson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 7, 2026
The impact of BRCA status on the efficacy of paclitaxel monotherapy in recurrent ovarian cancerGiorgia Russo, Adriana Ionelia Apostol, Ilary Ruscito, et al.
BMC Cancer|February 17, 2016
Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancerGabriel Schmid, Sara Notaro, Daniel Reimer, et al.
Pageof 24